ArticleBreast cancer research : BCR2019

Targeting promiscuous heterodimerization overcomes innate resistance to ERBB2 dimerization inhibitors in breast cancer.

Sean P Kennedy et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.